PSA Certified Announces New PSA Certified Level 4 Certification and Continued Partner Growth
4.4.2024 11:00:00 EEST | Business Wire | Press release
PSA Certified, the global security and evaluation framework for the connected device ecosystem, has today announced its highest certification level to date as it accelerates its mission to build assurance in connected devices. The new PSA Certified Level 4 iSE/SE certification offers enhanced protection of high value assets that can secure valuable AI models, future-proofing systems against new attack methods and rising security threats linked to the rapid adoption of edge AI. Its launch follows a period of strong momentum for PSA Certified which has become a trusted route for demonstrating security best practice and the assurance of connected devices.
David Maidment, Senior Director, Secure Devices Ecosystem at Arm (a PSA Certified co-founder):
“As the world embraces a new set of AI-enabled use cases, the value of data and assets has never been higher; nor has the importance of protecting them. The launch of PSA Certified Level 4 iSE/SE is testament to our commitment to helping the industry deploy security features that will protect devices and models from malicious changes and theft now, as well as over the next decade.”
As security cements its position as a business imperative, forward-looking companies are uplevelling their investment in security-by-design. PSA Certified has now surpassed the milestone of 200 certifications from nearly 90 technology providers, making it one of the most successful schemes to address connected device security.
The newly launched PSA Certified Level 4 Integrated Secure Enclave / Secure Element (iSE/SE) certification, already available at PSA Certified Labs, builds on the scheme’s momentum further and underpins a step change that can be used to protect valuable models and data during device boot and at rest (when models reside in secure storage). The level recognizes the use of a highly robust integrated Secure Enclave (iSE) or Secure Element (SE) - that acts as a trusted subsystem to the full Root of Trust (PSA RoT). By safeguarding critical cryptographic functions and key storage, OEMs can now ask for a RoT with a trusted subsystem that offers a ‘high’ level of attack resistance.
Benefits of PSA Certified Level 4 iSE / SE Certification include:
Protecting ML models at rest with highly robust crypto and key storage
- PSA Certified Level 4 iSE/SE considers more sophisticated attack methods in scope. Chips that achieve this new level could be used in an AI context to help protect valuable models and data at boot and rest: some chips will need protection from advanced fault injection and differential power analysis (up to and including EMFI, single laser and multi-glitching). PSA Certified Level 4 iSE/SE chips will also benefit from stronger cryptography of at least 128-bit strength. The new level offers a “high” level of protection of the PSA-RoT assets from physical or software attack.
- A trusted subsystem that achieves PSA Certified Level 4 iSE/SE can be used through composition in a PSA Certified Level 3+SE certification of the full PSA RoT security functionality. The PSA Certified Level 3 document has been updated to allow this new certification level.
PSA Certified Level 4 iSE/SE will help protect emerging use cases from sophisticated security attacks
- PSA Certified Level 4 iSE/SE offers additional security against more advanced attacks. Chips that offer this RoT provide a strong trust anchor that could be used to decrypt and verify OTA updates which help protect models in high-value systems.
- Industrial and safety-critical use cases need to support system recovery and stronger authentication: re-establishing integrity, confidentiality and availability are fundamental when rebooting systems and deploying OTA updates when faults are found, or upgrades are required. PSA Certified iSE/SE also mandates higher strength cryptography, which protects against more sophisticated attacks.
- Trust anchor for Edge AI and infrastructure chips, providing a “High” level of protection against physical and software attacks on critical assets that require a more robust Root of Trust to maintain system integrity.
A transparent certification scheme with a route to High, Substantial, and Basic levels of robustness and assurance, purpose-built for the SoC market
- PSA Certified offers a variety of robustness levels to match the market’s needs, all specifically designed for the electronics industry. By allowing a trusted subsystem to be certified as a component, and that certificate reused as part of a complete PSA RoT many times, chip vendors benefit from significant time and cost savings.
The first partner to aim for the PSA Certified Level 4 iSE/SE standard is Infineon, showcasing its commitment to developing IoT devices to the highest security-by-design standards.
Erik Wood, Senior Director, IoT Secure MCU Products at Infineon comments:
“In the age of AI, the risks of insecurity are immense and increasing. I’ve backed PSA Certified since launch and I am impressed by its success in uniting the technology ecosystem around the common goal of improving trust and security within the connected device ecosystem, while aligning to emerging government standards and legislation. The launch of PSA Certified Level 4 iSE/SE takes that one step further. With this new level, the electronics industry is better able to protect against the growing advancement of attack methods driven by the explosion of machine learning, generative AI and LLM.”
About PSA Certified
PSA Certified is a global partnership of security-conscious companies who are proactively building security best practices into devices at scale. Our security framework and independent third-party evaluation scheme was originally spearheaded by Arm and six other security ecosystem leaders (and now maintained by Applus+ Laboratories, CAICT, ECSEC Laboratory, ProvenRun, Riscure, SGS Brightsight, Serma, TrustCB, and UL) providing the resources needed to build upon the Root of Trust.
PSA Certified has scaled to become one of the fastest growing, most valued security ecosystems, globally. Being awarded ‘Ecosystem of the Year’ in the IoT Global Awards 2021 is testament to the role it has played in uniting industry, standards bodies, regulators and insurers together under one initiative. In doing so it’s accelerating the cross-industry collaboration required to untap the full potential of the IoT.
With 200 certifications from 88 partners, PSA Certified has democratized the adoption of security across the electronics industry, giving the ecosystem the confidence to innovate, while protecting consumers from the most common hacks.
Find out more: psacertified.org
1 A Certified Security Report 2023
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404517921/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
